116 related articles for article (PubMed ID: 7190063)
21. Tumor proliferation and chemotherapy in immunosuppressed mice.
Ghanta VK; Shrestha K; Durant JR; Hiramoto RN
Cancer Res; 1983 Mar; 43(3):1097-100. PubMed ID: 6825081
[TBL] [Abstract][Full Text] [Related]
22. Cell cycle age response of 9L cells to 1,3-bis(2-chloroethyl)-1-nitrosourea and modification by alpha-difluoromethylornithine.
Bjerkvig R; Oredsson SM; Marton LJ; Linden M; Deen DF
Cancer Res; 1983 Apr; 43(4):1497-500. PubMed ID: 6403224
[TBL] [Abstract][Full Text] [Related]
23. Surface immunoglobulins of lymphocytes in plasmacytoma. V. The effect of RNA-rich extract from mouse plasmacytoma MOPC 104E on the immune response.
Bhoopalam N; Chen Y; Yakulis V; Heller P
Clin Exp Immunol; 1976 May; 24(2):357-67. PubMed ID: 1277583
[TBL] [Abstract][Full Text] [Related]
24. Appearance of a variant of MOPC 104E which does not react with dextran B-1355s.
Folds JD
Immunol Commun; 1977; 6(4):385-94. PubMed ID: 407151
[TBL] [Abstract][Full Text] [Related]
25. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
[No Abstract] [Full Text] [Related]
26. Growth characteristics of MOPC-315 plasmacytoma and response to anticancer agents.
Valeriote F; Lynch R; Berger NA; White E; Coulter D
J Natl Cancer Inst; 1981 Jun; 66(6):1083-8. PubMed ID: 7017213
[TBL] [Abstract][Full Text] [Related]
27. Measurement of antibody release from single cells. 3. Rate of release of IgM from MOPC 104E plasmacytoma.
Ghanta VK; McGhee JR; Hamlin NM; Hiramoto RN
J Immunol; 1974 Jan; 112(1):266-70. PubMed ID: 4590822
[No Abstract] [Full Text] [Related]
28. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.
Neben S; Hellman S; Montgomery M; Ferrara J; Mauch P
Exp Hematol; 1993 Jan; 21(1):156-62. PubMed ID: 8435103
[TBL] [Abstract][Full Text] [Related]
29. Regulation of MOPC 104E by T cells and growth factors induced by C. parvum stimulation.
Shrestha K; Hiramoto RN; Ghanta VK
Int J Cancer; 1984 Jun; 33(6):845-50. PubMed ID: 6610653
[TBL] [Abstract][Full Text] [Related]
30. Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line.
Frondoza CG; Trivedi SM; Humphrey RL
Cancer Treat Rep; 1982 Jul; 66(7):1535-44. PubMed ID: 7093969
[TBL] [Abstract][Full Text] [Related]
31. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
Barker E; Mokyr MB
Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
[TBL] [Abstract][Full Text] [Related]
32. Tumoricidal and immunomodulatory activities of drugs and implications for therapy of mice bearing a late stage MOPC-315 plasmacytoma.
Berko R; Seissman K; Colvin M; Bocian RC; Ben-Efraim S; Dray S
Int J Immunopharmacol; 1988; 10(7):825-34. PubMed ID: 3235239
[TBL] [Abstract][Full Text] [Related]
33. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
34. Imuran-induced regression of plasma cell tumor MOPC-315.
Schlossberg M; Hollander VP
Cancer Res; 1973 Aug; 33(8):1953-6. PubMed ID: 4720804
[No Abstract] [Full Text] [Related]
35. In vitro analysis of the response of multicellular tumor spheroids exposed to chemotherapeutic agents in vitro or in vivo.
Yuhas JM; Tarleton AE; Harman JG
Cancer Res; 1978 Nov; 38(11 Pt 1):3595-8. PubMed ID: 698922
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy and rate of kill of tumor cells in a mouse plasmacytoma.
Hiramoto RN; Ghanta VK
Cancer Res; 1974 Jul; 34(7):1738-42. PubMed ID: 4833918
[No Abstract] [Full Text] [Related]
37. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
38. Host regulation of MOPC 104E plasmacytoma after reduction of tumor burden by total body irradiation.
Ghanta VK; Cox PJ; Hiramoto NS; Mills WB; Cohen HJ; Hiramoto RN
Cancer Invest; 1985; 3(3):217-23. PubMed ID: 3891028
[TBL] [Abstract][Full Text] [Related]
39. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
[TBL] [Abstract][Full Text] [Related]
40. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
